1. Scrip

Bill Gates On Vaccine Distribution Challenges, Overcoming Vaccine Hesitancy

 
• By Jessica Merrill

The public health advocate and billionaire philanthropist raised issues about how a mass COVID-19 vaccination effort is being handled so far in the US, speaking at the Stat Summit.

PARIS, FRANCE - APRIL 16: Co-chairman and co-founder of the The Bill and Melinda Gates Foundation, Bill Gates speaks to the media after his meeting with French president Emmanuel Macron.
Bill Gates addressed the Stat Summit • Source: Shutterstock

Billionaire philanthropist and public health advocate Bill Gates is concerned about US preparedness to end the COVID-19 crisis. The infrastructure for mass vaccination in the US is not coming together in a "rational fashion," he warned during a session at the Stat Summit on 17 November, as states have been given too little direction amidst a lack of federal leadership.

"It is so cacophonous. It could work out in a decent way,” Gates said, but, he added, “It doesn't appear...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.